Hassan Mansouritorghabeh
Overview
Explore the profile of Hassan Mansouritorghabeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khoshnegah Z, Siyadat P, Rostami M, Sheikhi M, Ghorbani M, Mansouritorghabeh H
J Thromb Thrombolysis
. 2024 May;
57(6):1018-1030.
PMID: 38722521
COVID-19 has been associated with alterations in coagulation. Recent reports have shown that protein C and S activities are altered in COVID-19. This may affect the complications and outcome of...
2.
Mazhari A, Khajavi M, Mansouritorghabeh H
Transfus Med Rev
. 2024 Apr;
38(2):150825.
PMID: 38579548
No abstract available.
3.
Valke L, Cloesmeijer M, Mansouritorghabeh H, Barteling W, Blijlevens N, Cnossen M, et al.
Eur J Drug Metab Pharmacokinet
. 2024 Feb;
49(2):191-205.
PMID: 38367175
Background: Hemophilia A patients are treated with factor (F) VIII prophylactically to prevent bleeding. In general, dosage and frequency are based on pharmacokinetic measurements. Ideally, an alternative dose adjustment can...
4.
Valke L, Verhagen M, Mulders B, Polenewen R, Blijlevens N, Jansen J, et al.
Thromb Res
. 2023 Oct;
231:112-120.
PMID: 37844518
Background: An inhibitor can develop in congenital hemophilia A (HA) patients against exogenous infused factor (F)VIII, whereas in acquired HA (AHA) inhibitors initially develop against endogenous FVIII. Inhibitors can be...
5.
Parsa-Kondelaji M, Mansouritorghabeh H
Thromb J
. 2023 Jul;
21(1):79.
PMID: 37501091
Objective: Antiplatelet drugs, such as Aspirin and Clopidogrel (Plavix) are effective in the primary prevention of thromboembolic events. They are commonly used to reduce the risk of recurrence of thromboembolism....
6.
Rostami M, Mansouritorghabeh H
J Thromb Thrombolysis
. 2023 May;
56(2):241-252.
PMID: 37219826
Heparin-induced thrombocytopenia (HIT) occurs in approximately 3% of patients receiving heparinoids. About 30-75% of patients with type 2 of HIT develop thrombosis as a result of platelet activation. The most...
7.
Rostami M, Mansouritorghabeh H
Expert Rev Hematol
. 2022 Jul;
15(8):747-755.
PMID: 35858633
Background: Antithrombin is considered as one of the accused markers for the development of thrombosis in patients with COVID-19. Because plasma levels of antithrombin vary in patients with COVID-19, a...
8.
Bari A, Mansouritorghabeh H
Clin Case Rep
. 2022 Mar;
10(3):e05558.
PMID: 35310320
A female was diagnosed with hemophilia A. She had undergone bilateral total knee arthroplasty. She had a history of numerous hemorrhages including hemarthrosis. After further investigations, the diagnosis of von...
9.
Bagherimoghaddam A, Rafatpanah H, Mansouritorghabeh H
Health Sci Rep
. 2022 Feb;
5(2):e519.
PMID: 35224220
Purpose: SARS-CoV-2 infection has spread in each corner of the world. Many health systems have dealt with it intensively. The complement system is an instrumental component in the inflammatory immune...
10.
Asiyabi S, Marashi S, Vahabpour R, Nejati A, Azizi-Saraji A, Mustafa A, et al.
Int J Hematol Oncol Stem Cell Res
. 2022 Jan;
15(3):192-198.
PMID: 35083000
Hemophilia is a well-known bleeding disorder with worldwide distribution. Replacement therapy, using plasma-derived or recombinant coagulation factors, comprises a gold standard regimen for the treatment. Regardless of the advancements made...